Related Experiment Video
Updated: Aug 6, 2026
10:13
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Xenon as neuroprotectant in acute stroke?
1Brain and Perception Laboratory, University of California, San Diego, 9500 Gilman Drive, 0109, La Jolla, CA 92093-0109, USA. ealtschuler@ucsd.edu
Medical Hypotheses
|June 27, 2001
Summary
Xenon shows promise as a neuroprotectant for acute stroke. Research suggests it could block N-methyl-D-aspartate (NMDA) receptors, reducing brain damage from glutamate toxicity.
Area of Science:
- Neuroscience
- Pharmacology
- Emergency Medicine
Background:
- Stroke is a leading global cause of death and disability.
- Acute stroke treatment focuses on limiting neuronal death.
- Glutamate excitotoxicity is a key mechanism of brain damage during stroke.
Purpose of the Study:
- To propose xenon as a potential neuroprotective agent for acute stroke.
- To explore xenon's mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist.
- To outline methods for investigating xenon's therapeutic potential in stroke.
Main Methods:
- Review of existing literature on xenon's pharmacological properties.
- Analysis of xenon's interaction with NMDA receptors.
- Discussion of preclinical and clinical study designs for xenon neuroprotection.
Main Results:
- Xenon acts as an NMDA receptor antagonist.
- This antagonism may mitigate glutamate-induced neurotoxicity.
- Existing research supports further investigation into xenon for stroke.
Conclusions:
- Xenon is a viable candidate for neuroprotection in acute stroke.
- Further research is warranted to establish xenon's efficacy and safety.
- Xenon offers a novel therapeutic avenue for stroke management.
